TrialPloS one2013

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.

Geert Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.